Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Olema Oncology Reports 15.5-Month Median Progression-Free Survival With Palazestrant Plus Ribociclib In ER-Positive, HER2-Negative Metastatic Breast Cancer At ESMO 2025

Author: Benzinga Newsdesk | October 20, 2025 04:26am

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups
Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients
In the 120 mg palazestrant cohort among patients with prior CDK4/6i treatment, median PFS was 9.2 months in patients with ESR1 wild-type tumors and 13.8 months in patients with ESR1 mutant tumors
Combination continues to demonstrate favorable tolerability and a safety profile consistent with the known profiles of each drug
Data support the ongoing Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline advanced or metastatic breast cancer

Posted In: OLMA